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Abstract
Objective—To compare patients’ global assessments of change in knee, hip, and back symptoms
with actual changes over time in pain, function, and radiographic severity.
Methods—Participants (n=894, 80% female, mean age=66 years) completed two assessments
(mean of 4 years apart) as part of a study on the genetics of generalized osteoarthritis. At both
assessments, participants completed the Western Ontario and McMaster Universities OA Index
(WOMAC), and radiographic severity was assessed for knees, hips, and low back. At the second
assessment, participants described changes in knee, hip, and low back symptoms as Worse, Better,
Same, or Never Had Symptoms. Analysis of covariance models examined mean changes in
WOMAC scores and radiographic severity according to categories of the global assessment
measures. Statistical significance was examined for linear trend.
Results—Mean WOMAC total, pain, and function scores decreased (indicating improvement)
among participants who indicated joint symptoms were Better; showed little change among those
who reported symptoms were the Same/Never Had Symptoms; and increased among those who
reported symptoms were Worse. For all analyses except the comparison of WOMAC pain change
according to global assessment of low back symptom change, there was a statistically significant
linear trend (p<0.05). Patterns were similar for changes in radiographic severity, but the tests of
linear trend were not statistically significant.
Conclusion—Results support the concordance of these global assessments of joint symptom
change with actual changes in self-reported symptoms. These global assessments may be useful
for assessing change over time when baseline data are unavailable.
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Primary outcomes for most clinical trials of osteoarthritis (OA) therapies, as well as
longitudinal observational studies, involve examination of changes in some multiple-item
self-report questionnaire (such as the Western Ontario and McMaster Universities OA
Index) (1). While these types of outcome assessments are well established and clearly
important, there is increasing awareness of the value provided by patients’ global
assessments of symptom change over time or in response to treatment. The Osteoarthritis
Research Society International (OARSI), the Outcome Measures in Rheumatology Clinical
Trials group (OMERACT), and others have specifically recommended including patient
global assessment as a key outcome in OA trials (2–5).
Some studies of hip and knee OA have incorporated patient global assessments of change in
response to treatment (6–8). However, there have been few studies examining the validity of
global assessment of change measures, compared with other standard outcome measures
used in OA research. Additional evaluation of such measures is warranted, since global
assessments of change are useful in the context of not only clinical trials, but also in
epidemiological studies and clinical decision making. Global assessments of change are
particularly useful for assessing symptom change over time when no baseline data are
available.
We previously reported on the construct validity of a global assessment of change measure
for hand OA in a large study of the Genetics of Generalized OA (GOGO) (9). This study
supported the validity of the global assessment of hand symptom change based on
significant associations with changes in grip strength, pinch strength, and AUStralian
CANadian Osteoarthritis Hand Index (AUSCAN) (10, 11) scores. The current study extends
this work, examining the construct validity of global assessment of change items for hip,
knee, and back symptoms. Specifically, we examined associations of these global
assessments of change with changes in WOMAC scores and radiographic severity.
Methods
Subjects
All participants were enrolled in the GOGO study (12). The primary objective of GOGO
was to identify OA susceptibility genes through genotyping and linkage analysis of OA
affected sibling pairs. GOGO involved a consortium of seven clinical research sites in the
United States and United Kingdom (13). Participants included in these analyses were from
three GOGO sites: Duke University and the University of North Carolina at Chapel Hill in
the US, and the University of Nottingham in the UK. These three sites were included
because they collected the global assessment of change questions, as well as WOMAC
scores at baseline and follow-up.
The overall sample size for the GOGO study was based on providing adequate power to
detect genes of moderate to large effect (12). All families recruited for the GOGO study had
at least two siblings with bilateral hand osteoarthritis, defined as bony enlargement of at
least one distal interphalangeal joint (DIP), and bony enlargement of 2 or more other
interphalangeal joints or carpometacarpal (CMC) joints. All radiographs were read by a
single reader (JBR). Participants were excluded if they had self-reported or x-ray evidence
of rheumatoid arthritis, systemic lupus erythematosis, psoriasis, or gout of the hands, hips or
knees. Among 1,569 GOGO participants who met criteria for these analyses at baseline, 924
(59%) completed questionnaires and at least one radiograph (knee, hip, or spine) at follow-
up. The mean time between baseline and follow-up assessments was 4.0 years (standard
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deviation (SD) = 0.9). Those who did and did not participate in follow-up assessments did
not differ significantly according to baseline WOMAC total, pain or function scores, body
mass index (BMI), or gender. Those who did not participate in follow-up assessments were
older than those who did participate (means = 68 years and 66 years, respectively, p<0.01).
For these analyses we also excluded individuals who had had knee or hip replacement
surgery between baseline and follow-up assessments and those who did not answer any of
the global assessment of change questions, resulting in a final sample size of n = 894.
Global Assessment of Change Questions
At the follow-up visit, all participants were asked (separately for each joint), “Since your
last GOGO visit, has there been any change in pain, aching, or stiffness in your: LEFT
KNEE; RIGHT KNEE; LEFT HIP; RIGHT HIP; or LOW BACK?” Four responses were
possible: 1. Worse, 2. About the same, 3. Better, and 4. No symptoms at the first GOGO
visit and still no symptoms. These questions were patterned after a global assessment of
change scale for assessing shortness of breath (14).
Because our analyses involved comparing these global assessments of change with
WOMAC scores, which are not joint specific, and because we did not find any substantial
differences in analyses of right vs left knees or right vs. left hips, we created composite
global assessment categories and scores that combined information for both knees and both
hips. Specifically, we grouped people into the following categories: 1. One or Two Knees
Better (No Knee Worse); 2. Both Knees Same or Never Had Symptoms; 3. One Knee
Worse; 4. Two Knees Worse. The same categories were created for hips. For low back
global assessments (a measure without laterality), we grouped people into three categories:
1. Better; 2. About the same or Never Had Symptoms; 3. Worse. In addition to these joint-
specific categories, we created a variable indicating the total number of joint sites each
participant reported as being Worse (0–5; summing 2 hips, 2 knees, and low back).
WOMAC
We examined associations of global assessment of change questions with changes in
WOMAC scores (between baseline and follow-up GOGO visits). The WOMAC is a
validated and reliable scale designed to assess pain, stiffness, and function in lower
extremity OA (range: 0–96) (1, 15). In addition to examining the total WOMAC scores, we
separately examined the WOMAC pain (range: 0–20), and physical function (range: 0–68)
subscales. To examine changes in WOMAC scores, we subtracted baseline scores from
follow-up scores, so that positive change scores indicated worsening pain and function and
negative scores indicated less pain and better function.
Radiographs
Knees: A fixed-flexion posteroanterior knee radiograph was taken with the SynaFlexer™ x-
ray positioning frame (Synarc, San Francisco, CA) (16) with 10° caudally angulated x-ray
beam. Hips: An anteroposterior view of the pelvis was performed with the participant supine
and feet internally rotated 10 degrees. Spine: A lateral view of the lumbar spine (L1–L5) was
performed with the participant recumbent, with left side down. Knee, hip, and back
radiographs were read by a single reader (JBR), with both baseline and follow-up
radiographs being read at one time but with the reader blinded to time point. Participants
were excluded from knee and radiographs in cases of joint replacement and amputation. Hip
radiographs were performed in women of child-bearing potential after confirming a negative
pregnancy test. Lumbar spine x-rays at both baseline and follow-up were performed at the
US sites only (Duke and University of North Carolina).
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We examined associations of global assessment of change questions with changes in
radiographic severity between baseline and follow-up GOGO visits. For knees, radiographic
severity was defined as the sum of scores for osteophytes (0=none to 3=severe) and joint
space narrowing (JSN; 0=none to 3=severe) at the medial and lateral aspects of the tibia and
femur, and at the medial and lateral patellofemoral joint; possible scores of 0–48 for two
knees. For hips, radiographic severity was defined as the sum of scores for osteophytes
(0=none to 3=severe) at the lateral and medial aspects of the femur and acetabulum, as well
as medial, superior, and axial JSN (0=none to 3=severe), possible scores of 0–42 for two
hips. Sums of osteophytes and JSN were significantly correlated with Kellgren Lawrence
grades (17) for hips and knees (Pearson r’s = 0.76–0.92, p < 0.0001). Lumbar spine
radiographs were scored for the presence and severity of vertebral osteophytes and disc
narrowing (for analyses also referred to as JSN). Radiographic severity for the lower back
was defined as the sum of osteophytes (0=none to 3=severe) and JSN (0=none to 3=severe)
for each of the lumbar spine levels (L1–L5), for possible scores of 0–30. For all three joint
groups we also separately examined associations of global assessment of change scores with
changes in osteophyte and JSN scores.
Additional Participant Characteristics
We included the following characteristics in multivariable models: baseline participant age,
gender, baseline BMI (calculated from measured height and weight), baseline radiographic
severity (as defined above), and time between baseline and follow-up assessments.
Analyses
We performed ANCOVA models to examine differences in mean changes in WOMAC
total, pain subscale, and function subscale scores, as well as changes in radiographic
severity, according to the combined global assessment of change categories for hips and
knees (4 categories each for hips and knees: One or Two Knees/Hips Better; Both Knees
Same or Never Had Symptoms; One Knee Worse; Two Knees Worse), as well as global
assessment of change categories for low back (Better, Same/Never Had Symptoms, or
Worse). Similarly, we used ANCOVA analyses to examine mean changes in WOMAC
scores according to the number of joint sites reported as Worse (0–5). Covariates included
age, gender, BMI (calculated from measured height and weight), baseline radiographic
severity (as defined above), and time between baseline and follow-up assessments. We were
primarily interested in whether WOMAC and radiographic severity change scores varied
linearly across the global assessment of change categories (rather than whether there was an
overall difference among categories) and therefore report the p-value for linear trend in each
of these analyses. All analyses were conducted using SAS version 9.1 (SAS Institute, Cary,
NC), and statistical significance was evaluated at the p<0.05 level.
Results
The sample (n = 894) was relatively equally distributed across three GOGO study sites:
Duke University (33%), University of North Carolina Chapel Hill (33%), University of
Nottingham (34%). Participants were 80% female, the mean age was 66.0 years (SD=8.4),
and the mean body mass index was 28.4 kg/m2 (SD = 5.6). Between baseline and follow-up,
there were small increases in mean scores for WOMAC total (25.3, SD = 20.1 vs. 27.5, SD
= 20.8), pain (5.2, SD = 4.4 vs. 5.6, SD = 4.7), and function (16.4, SD = 13.8 vs. 18.0, SD =
14.2).
Among those who had knee radiographs at baseline (n = 852), 43% had OA in at least one
knee. The mean radiographic severity scores across both knees at baseline and follow-up
were 3.2 (SD = 3.7) and 3.8 (SD=3.7), respectively; mean osteophyte scores were 2.0 (SD =
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2.3) and 2.3 (SD = 2.1), respectively; mean JSN scores were 1.6 (SD = 2.1) and 2.0 (SD =
2.2), respectively. Among those who had hip radiographs at baseline (n=862), 37% had OA
in at least one hip. The mean radiographic severity scores across both hips at baseline and
follow-up were 3.2 (SD = 2.6) and 3.5 (SD=2.8), respectively; mean osteophyte scores were
2.6 (SD = 1.5) and 2.9 (SD = 1.7), respectively; mean JSN scores were 0.5 (SD = 1.3) and
0.6 (SD = 1.5), respectively. Among those who had lumbar spine radiographs at baseline (n
= 502, performed at Duke and University of North Carolina sites only), 56% had OA. The
mean radiographic severity scores for the lumbar spine at baseline and follow-up were 2.9
(SD = 2.7) and 3.6 (SD = 2.9), respectively; mean osteophyte scores were 1.1 (SD = 1.3)
and 1.5 (SD = 1.4), respectively, and mean JSN scores were 1.8 (SD = 1.5) and 2.2 (SD =
1.6), respectively.
Participants’ responses to global assessment of symptom change items for knees, hips, and
low back are summarized in Table 1. Very few participants reported that symptoms got
better for any of the joint groups. About 47% of participants reported that symptoms were
worse in at least one knee, about 43% reported that symptoms were worse in at least one hip,
and 43% reported that symptoms were worse at the low back. About 70% reported that at
least one joint (hip, knee, or low back) got worse.
Changes in WOMAC total, pain, and function subscale scores showed expected patterns
according to global assessment of change categories (Table 2, Figure 1). Specifically,
WOMAC scores increased (indicating worsening symptoms) among those who indicated
symptoms were worse than at baseline in at least one hip or knee, as well as at the low back.
Furthermore, increases in WOMAC scores were greater among those who indicated that
both hips or both knees had worsened, compared with just one hip or one knee getting
worse. There were very small changes in WOMAC scores among those who reported that
their knees had gotten better. However, there were larger decreases in WOMAC scores
among those who reported that hip or low back symptoms were better. Tests of linear trend
were statistically significant for all WOMAC scores for knees and hips, as well as for
WOMAC total and function scores for the low back.
Changes in knee radiographic severity scores also generally showed expected patterns
according to global assessment of change categories (Table 2). While mean radiographic
severity scores increased for all global assessment of change categories, there were larger
changes (i.e., greater worsening of radiographic severity) among those who indicated that
symptoms had gotten worse. These patterns were observed for the overall radiographic
severity score, as well as for changes in JSN and osteophytes separately. However, linear
trend tests were not statistically significant for any of these analyses.
Changes in WOMAC total, pain, and function subscale scores showed expected patterns
according to the number of joints participants reported were Worse (Table 3, Figure 1).
Participants who reported that no joints had gotten worse had small decreases in WOMAC
scores (indicating slight improvement), and participants who reported that 1 or more joints
were Worse had increased WOMAC scores (indicating worsening symptoms). WOMAC
scores generally increased more with the number of joints being reported as Worse, except
that the mean increases in WOMAC total and pain scores were smaller for those with 5 vs. 4
worse joints. Tests of linear trend were statistically significant for all WOMAC scores.
Discussion
This study examined associations of patient global assessments of hip, knee, and low back
symptom change (better, same/never had symptoms, or worse) with changes over time
(mean of 4 years) in WOMAC scores and radiographic severity. Changes in WOMAC
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scores showed the expected patterns according to these global assessments. Specifically,
mean WOMAC total, pain, and function scores decreased among participants who indicated
joint symptoms were better at follow-up, showed little change among those who reported
symptoms were the same, and increased among those who indicated symptoms were worse.
For all analyses except the comparison of changes in WOMAC pain scores according to
global assessment of low back symptom change, statistical tests indicated a significant linear
trend. Notably, for both hips and knees, WOMAC change scores were higher (indicating a
greater degree of worsening in symptoms) among participants who reported that both hips/
knees had gotten worse, compared with just one hip/knee. Since the WOMAC is most often
used in the context of hip or knee OA, it is noteworthy that there was also good agreement
between the global assessment of low back symptom change and changes over time in
WOMAC scores. A prior study also showed that in cross-sectional analyses, WOMAC
scores were strongly associated with low back pain (18). Furthermore, changes in WOMAC
total, pain, and function scores showed the expected patterns when compared according to
the total number of joints (hip, knee, and low back) participants reported as being Worse.
Linear trends were statistically significant in these analyses also. This lends further support
for the ability of the global assessment measure to capture overall changes in lower
extremity symptoms and function.
Changes in total radiographic severity scores, osteophytes scores, and JSN scores also
generally showed the expected patterns according to global assessment of change categories,
though linear trend tests were not statistically significant. There are several possible reasons
for this weaker association, including the general lack of strong correlation between
radiographic severity and joint symptoms (19) and the fact that factors other than bone
changes visible by radiograph can affect symptom severity (20). In addition, there were
fairly small changes overall in radiographic severity over time.
There are several important strengths and potential applications of this global assessment of
change measure. First, this item asks individuals to recall change in a very specific aspect of
health, and studies show that condition-specific measures are more sensitive to change than
measures of global health status (21, 22). Second, this item is administered at a single time
but assesses change in joint symptoms over a specified time interval. Therefore it may be
useful for assessing symptom change when baseline data are not available. While the
categories in this measure are broad, they are useful for simply discriminating between
individuals whose symptoms have remained stable, worsened, or improved over a specified
period of time. This type of information can be particularly useful in large, cross-sectional
epidemiological studies. Third, because this is a very brief measure, it can be readily used in
clinical settings to monitor patients’ responses to new treatments.
There are some general limitations to recall-based outcome measures. First, recall of prior
symptom severity may be difficult for some individuals, particularly for lengthier recall
periods. Second, there may be recall bias associated with these measures. Some research
suggests that assessments of change and prior symptoms may be influenced by the severity
of present symptoms (23–26). A third possible limitation is “response shift,” where people
undergo adaptation to their chronic condition and redefine its severity or impact. These
phenomena need consideration for longitudinal studies spread over several years (27). There
are some other limitations to these analyses. First, due to the nature of the study, very few
participants experienced improvements in symptoms. Additional research is needed to test
the usefulness of these global assessment of change questions in contexts where
improvement is expected, such as clinical trials of medications or other treatments. Second,
the radiographic severity score used in these analyses (the sum of the individual
radiographic feature scores for JSN and osteophyte) has not been commonly used or
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validated. However, we found that this score was strongly correlated with Kellgren-
Lawrence grade, a widely used and validated scoring system.
In summary, this study showed that simple global assessments of symptom change for the
knee, hip, and back were significantly associated with actual changes in WOMAC total,
pain, and function scores for all joint groups and also showed expected patterns with respect
to changes in radiographic severity. This provides support for the utility of these measures
and extends our previous work supporting this same global assessment for hand symptom
change (9). Additional research should examine the validity of these measures in other
samples, including both epidemiologic studies and clinical trials.
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Changes in WOMAC scores over time according to patient global assessments of joint
symptom change.
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Table 1
Global Assessments of Change
Knee n (%)
Left
 Better (%) 48 (5.4)
 Same (%) 280 (31.3)
 Worse (%) 310 (34.7)
 Never Had Symptoms (%) 256 (28.6)
Right
 Better (%) 46 (5.2)
 Same (%) 284 (31.8)
 Worse (%) 337 (37.7)
 Never Had Symptoms (%) 227 (25.4)
One or Two Knees Better (No Knee Worse) 50 (5.6)
Both Knees Same or Never Had Symptoms 417 (46.6)
One Knee Worse 207 (23.2)
Both Knees Worse 220 (24.6)
Hip
Left
 Better (%) 15 (1.7)
 Same (%) 273 (30.5)
 Worse (%) 253 (28.3)
 Never Had Symptoms (%) 353 (39.5)
Right
 Better (%) 15 (1.7)
 Same (%) 267 (29.9)
 Worse (%) 280 (31.3)
 Never Had Symptoms (%) 332 (37.1)
One or Two Hips Better (No Hip Worse) 20 (2.2)
Both Hips Same or Never Had Symptoms 193 (55.2)
One Hip Worse 229 (25.6)
Both Hips Worse 152 (17.0)
Back
 Better (%) 33 (3.7)
 Same (%) 315 (35.2)
 Worse (%) 383 (42.8)
 Never Had Symptoms (%) 163 (18.2)
Number of Joints Worse
 0 263 (29.4)
 1 176 (19.7)
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Knee n (%)
 2 192 (21.5)
 3 124 (13.9)
 4 64 (7.2)
 5 75 (8.4)
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